For each case, one clone detected in the pre-treatment tumour biopsy stably maintained a clonal prevalence value of 1.0 (i.e. all cancer cells harbour the mutations) across all timepoints, with each containing known HER2+ breast cancer specific driver genes (Supplementary Table 14). This evidence concerns the gene ERBB2 and neoplasm.